Index

Note: Page numbers of article titles are in boldface type.

A

Acid(s)
boronic (See Boronic acid(s))

Acinetobacter baumannii
carbapenem-resistant
in the community, 381–382

Agents of last resort, 391–414. See also Polymyxin(s)

Agriculture
antibiotics and, 317–318

AIDS
antibiotic-resistant infections in, 478–481

Aminoglycoside(s)
in ESBL–producing Enterobacteriaceae infections management
in hospital settings, 358–359

Aminoglycoside resistance
acquired 16S–RMTase gram-negative bacteria related to, 523–537 (See also 16S ribosomal RNA methyltransferases (RMTase), in gram-negative bacteria)
introduction, 523–524
mechanisms of, 524–525

Antibiotic(s)
agriculture and, 317–318
new
in ASPs for MDR infections, 548

Antibiotic resistance
evolution of, 314–317
global and local impact of, 313–322
societal burden of, 318–319
in Streptococcus pneumoniae
in HIV patients, 480

Antibiotic-resistant infections
in Enterococcus spp.
in HIV patients, 480
in HIV and AIDS, 478–481
in immunocompromised hosts, 465–489 (See also Immunocompromised hosts, antibiotic-resistant infections in)
in SOT
treatment challenges, 466–472

Antimicrobial stewardship
in prevention of polymyxin resistance, 404–405

Antimicrobial stewardship programs (ASPs)
in MDR infections management
costs related to, 542–543

Infect Dis Clin N Am 30 (2016) 553–565
http://dx.doi.org/10.1016/S0891-5520(16)30036-8 id.theclinics.com
0891-5520/16/$ – see front matter
Antimicrobial (continued)
  evidence of, 543–548
  evolving role of, 539–551
  impact of, 542–543
  introduction, 539–540
  need for, 540–541
  new antimicrobial agents in, 548
  success of
collaboration in, 541–542
Antimicrobial susceptibility testing (AST) methods
  in defining resistance to gram-negatives in clinical microbiology laboratory, 324–325
  armA gene, 527–529
  ASPs. See Antimicrobial stewardship programs (ASPs)
  AST methods. See Antimicrobial susceptibility testing (AST) methods
Avibactam
  in the clinic, 445–447

B
Bacillus(i)
  gram-negative
  polymyxin-resistant
  clinical epidemiology of, 395–398
Bacteremia
  MRSA and
treatment of, 491–507 (See also Methicillin-resistant Staphylococcus aureus (MRSA), bacteremia due to)
Bacteria
  MDR
  in the community, 377–390 (See also Multidrug-resistant (MDR) bacteria)
  introduction, 377–378
Bisthiazolidine (BTZ) inhibitors
  in preclinical development, 457
  blaCTX–producing Escherichia coli
  in the community
  clonal expansion of, 352
Blue-Carba test
  in defining resistance to gram-negatives in clinical microbiology laboratory, 325
Boronic acid(s)
  in preclinical development, 449–452
  Boronic acid β-lactamase inhibitors
  making great strides in, 448–449

C
Carba NP test
  in defining resistance to gram-negatives in clinical microbiology laboratory, 325
Carbapenem(s)
  in ESBL–producing Enterobacteriaceae infections management
  in hospital settings, 355–356
Carbapenemase
  rapid biochemical tests in detection of
    in defining resistance to gram-negatives in clinical microbiology laboratory, 325
Carbapenem-producing enterobacteriaceae
  in the community, 384
Carbapenem-resistant Acinetobacter baumannii
  in the community, 381–382
Ceftaroline
  in bacteremia-related MRSA management, 497–498
Ceftolozane-tazobactam, 443–445
Cephalosporin(s)
  in ESBL–producing Enterobacteriaceae infections management
    in hospital settings, 356
    fifth-generation
      in bacteremia-related MRSA management, 497–498
    siderophore
      in clinical development, 455–456
    3'-thiobenzoyl
      in preclinical development, 456
Cephamycins
  in ESBL–producing Enterobacteriaceae infections management
    in hospital settings, 357
Clavam(s)
  novel
    in preclinical development, 452–453
Clinic(s)
  new β-lactamase inhibitors in, 441–464 (See also specific agents and β-lactamase inhibitors, new, in the clinic)
Clinical microbiology laboratory
  in defining resistance to gram-negatives
    changing role of, 323–345
      discussion, 333
      introduction, 323–324
      methods in, 324–330
        LAMP, 327–328
        MALDI-TOF MS, 330
        microarrays, 329
        NGS, 328
        rapid biochemical tests to detect ESBL and carbapenemase producers, 323
        single and multiplex endpoint PCRs, 325–326
        single and multiplex real-time PCRs, 326–327
        standard AST procedures, 324–325
        WGS, 328–329
    technologies in development, 330–333
      FilmArray, 332
      FISH, 332
      microfluidic technologies, 331
      nanotechnology, 331
      PCR/ESI MS, 332–333
Clinical (continued)
rapid antimicrobial susceptibility testing, 330–331
rapid WGS, 332
Colistin, 391–414. See also Polymyxin(s)
Community(ies)
clonal expansion of blaCTX-M–producing Escherichia coli in, 352
MDR bacteria in, 377–390 (See also Multidrug-resistant (MDR) bacteria, in the community)
Community-associated infections
MDR bacteria and, 378
CTX-M–producing Escherichia coli
in nonhospital settings
outbreak of, 350–352

D
Dalbavancin
in bacteremia-related MRSA management, 496
Daptomycin
in bacteremia-related MRSA management, 496–497
combination therapy with, 500–503
resistance to VRE infections
mechanisms in mediation of, 421–423
in VRE management
combination therapy with, 427–428
Diazabicyclooctanones, 445
in the clinic
pioneer, 445–447
on the horizon, 448
in preclinical development, 448
DR-TB. See Drug-resistant tuberculosis (DR-TB)
Drug-resistant tuberculosis (DR-TB), 509–522
background of, 509–510
treatment of
clinical drug development in
alternate approaches to, 515–516
clinical trials in, 513–515
current approaches, 510–513
resistance mechanisms in, 510–511
second-line agents in, 511–513
standard therapy in, 511
Dual β-lactam combinations
in VRE management, 427

Ε
Enterobacteriaceae
carbapenem-producing
in the community, 384
ESBLs produced by
in the community, 383–384
Enterobacteriaceae infections

ESBL–producing
continuing plague of, 347–375 (See also Extended-spectrum β-lactamase (ESBL)–producing Enterobacteriaceae infections)

Enterococcal infections, 417–418
Enterococci
vancomycin-resistant (See Vancomycin-resistant enterococci (VRE))

*Enterococcus* spp.
antibiotic resistance in
in HIV patients, 480

ESBL NDP test
in defining resistance to gram-negatives in clinical microbiology laboratory, 325

ESBLs. See Extended-spectrum β-lactamase (ESBLs)

Escherichia coli

*blaCTX-M*–producing
in the community
clonal expansion of, 352

CTX-M–producing
in nonhospital settings
outbreak of, 350–352

Extended-spectrum β-lactamase(s) (ESBLs)

emergence of, 348–349
enterobacteriaceae producing
in the community, 383–384
isolated impact on patients’ clinical outcomes, 355
rapid biochemical tests in detection of
in defining resistance to gram-negatives in clinical microbiology laboratory, 325
worldwide prevalence of, 349

Extended-spectrum β-lactam (ESBL) infections
in HIV patients, 481

Extended-spectrum β-lactam (ESBL)–producing Enterobacteriaceae infections. See also specific infections
in ambulatory settings
treatment of, 359
continuing plague of, 347–375
introduction, 348
future perspective on, 360
in hospital settings
treatment of, 355–359
aminoglycosides in, 358–359
β–lactam–β-lactamase inhibitors combinations in, 357–358
carbapenems in, 355–356
cephalosporins in, 356
cephamycins in, 357
fluoroquinolones in, 356–357
polymyxins in, 359
tigecycline in, 359
introduction, 348
outside of hospital settings
predictors of, 353–355

SHVs
Extended-spectrum (continued)
  historic evolution of, 349–350
  TEM
  historic evolution of, 349–350

F
F51-1671
  in preclinical development, 456–457
F51-1686
  in preclinical development, 456–457
Fifth-generation cephalosporins
  in bacteremia-related MRSA management, 497–498
FilmArray
  in defining resistance to gram-negatives in clinical microbiology laboratory, 332
FISH. See Fluorescence in situ hybridization (FISH)
  Fluorescence in situ hybridization (FISH)
    in defining resistance to gram-negatives in clinical microbiology laboratory, 332
Fluoroquinolones
  in ESBL–producing Enterobacteriaceae infections management
    in hospital settings, 356–357
Fosfomycin
  in bacteremia-related MRSA management
    combination therapy with, 503

G
Glycopeptide(s)
  in bacteremia-related MRSA management, 492–497
Glycylcyclines
  resistant to VRE infections
    mechanisms in mediation of, 425
Gram-negative(s)
  resistance to
    changing role of clinical microbiology laboratory in defining, 323–345 (See also Clinical microbiology laboratory, in defining resistance to gram-negatives)
Gram-negative bacilli
  polymyxin-resistant
    clinical epidemiology of, 395–398

H
Health care–associated MDR infections, 378–379
HIV
  antibiotic resistance to Enterococcus spp. in patients with, 480
  antibiotic resistance to Streptococcus pneumoniae in patients with, 480
  antibiotic-resistant infections in patients with, 478–481
  ESBL pathogens in, 481
  MRSA in
    incidence and risk factors for, 479–480
I

Immune system
  host susceptibility to bacterial pathogens in, 466

Immunocompromised hosts
  antibiotic-resistant infections in, 465–489
    HIV and AIDS, 478–481 (See also AIDS; HIV)
    introduction, 465–466
    mortality risks associated with, 472
    treatment challenges, 465–489
  neutropenic host, 472–478 (See also Neutropenic host)

Infection(s). See also specific types
  antibiotic resistant
    in immunocompromised hosts, 465–489 (See also Immunocompromised hosts, antibiotic-resistant infections in)
    enterococcal, 417–418
  MDR
    management of
      ASPs in, 539–551 (See also Antimicrobial stewardship programs (ASPs), in MDR infections management)

Infection control
  in prevention of polymyxin resistance, 404

L

β-Lactam(s)
  changing partner in
    ceftolozane-tazobactam, 443–445

β-Lactamase inhibitor(s)
  boronic acid
    making great strides in, 448–449
    development of
      obstacles in, 442–443
    new
      in the clinic, 441–464

β-Lactamase inhibitor medicinal chemistry
  future of, 445

β-Lactam-avibactam combinations
  resistance to, 447–448

β-Lactam–β-lactamase inhibitor combinations
  current clinically available
    fall of, 441–442
    in ESBL–producing Enterobacteriaceae infections management
      in hospital settings, 357–358

β-Lactam combinations
  dual
    in VRE management, 427

LAMP. See Loop-mediated isothermal amplification (LAMP)

Lipoglycopeptides
  resistant to VRE infections
    mechanisms in mediation of, 424
Lipoglycopeptides (continued)
  semisynthetic
  in bacteremia-related MRSA management, 493–496
Loop-mediated isothermal amplification (LAMP)
  in defining resistance to gram-negatives in clinical microbiology laboratory, 327–328

M
MALDI-TOF MS. See Matrix-assisted laser desorption ionization–time of flight mass spectroscopy (MALDI-TOF MS)
Matrix-assisted laser desorption ionization–time of flight mass spectroscopy (MALDI-TOF MS)
  in defining resistance to gram-negatives in clinical microbiology laboratory, 330
MDR. See Multidrug-resistance (MDR); Multidrug-resistant (MDR)
MDROs. See Multidrug-resistant organisms (MDROs)
ME1071
  in preclinical development, 457
Metallo-β-lactamase–specific inhibitors
  in preclinical development, 457
Methicillin-resistant Staphylococcus aureus (MRSA)
  bacteremia due to
    introduction, 491–492
    treatment of, 491–507
      ceftaroline in, 497–498
      combination therapy in, 499–503
      dalbavancin in, 496
      daptomycin in, 496–497
      fifth-generation cephalosporins in, 497–498
      glycopeptides and semisynthetic lipoglycopeptides in, 492–497
      oritavancin in, 493, 496
      oxazolidinones in, 498–499
      telavancin in, 496
      tigecycline in, 499
      vancomycin in, 492–493
  in the community, 380
  in HIV patients
    incidence and risk factors for, 479–480
Microarray(s)
  in defining resistance to gram-negatives in clinical microbiology laboratory, 329
Microfluidic technologies
  in defining resistance to gram-negatives in clinical microbiology laboratory, 331
Monobactam(s)
  in preclinical development, 455
    as promising β-lactamase inhibitors, 453–454
MRSA. See Methicillin-resistant Staphylococcus aureus (MRSA)
Multidrug-resistance (MDR)
  costs related to, 542–543
  management of
    ASPs in, 540–541
      evidence of, 543–548
Multidrug-resistant (MDR) bacteria
in the community, 377–390
  carbapenem-producing enterobacteriaceae, 384
  carbapenem-resistant *Acinetobacter baumannii*, 381–382
  community-onset, 378
  enterobacteriaceae producing ESBLs, 383–384
  health care–associated, 378–379
  introduction, 377–378
  MDR *Pseudomonas aeruginosa*, 382–383
  MRSA, 380
  nosocomial infections, 378
  prevention of, 384–385
  transition from nosocomial to community pathogen, 379–380
  VRE, 380–381
  introduction, 377–378
Multidrug-resistant (MDR) infections
  management of
    ASPs in, 539–551 (See also Antimicrobial stewardship programs (ASPs), in MDR infections management)
Multidrug-resistant organisms (MDROs)
  morbidity and mortality associated with, 471–472
  in neutropenic hosts, 473–478
Multidrug-resistant (MDR) *Pseudomonas aeruginosa*
  in the community, 382–383

N
Nanotechnology
  in defining resistance to gram-negatives in clinical microbiology laboratory, 331
Neutropenic host, 472–478
  in cancer patients
    MDROs in
      prevalence of, 473–475
  febrile
    MDROs in
      risk factors for, 475–476
      inappropriate empiric antibiotics in, 476–477
    MDROs in
      morbidity and mortality associated with, 477–478
Next-generation sequencing (NGS)
  in defining resistance to gram-negatives in clinical microbiology laboratory, 328
NGS. See Next-generation sequencing (NGS)
Nosocomial infections
  MDR bacteria and, 378
NpmA, 531

O
16S ribosomal RNA methyltransferases (RMTase)
  emergence of, 523–537
  in gram-negative bacteria, 526–531
    armA gene, 527–529
16S (continued)
clinical implications of, 531–532
NpmA, 531
prevalence of, 531
RmtA, 529
RmtB, 529–530
RmtC, 530
RmtD, 530
RmtE, 530
RmtF, 530–531
RmtG, 531
RmtH, 531
16S–RMTase. See 16S ribosomal RNA methyltransferases (RMTase)
OP0595
on the horizon, 448
Oritavancin
in bacteremia-related MRSA management, 493, 496
Oxazolidinones
in bacteremia-related MRSA management, 498–499
resistance to VRE infections
mechanisms in mediation of, 423–424
P
PCR/ESI MS. See Polymerase chain reaction/electrospray ionization mass spectroscopy (PCR/ESI MS)
PCRs. See Polymerase chain reactions (PCRs)
Phosphonate(s)
in preclinical development, 453
Polymerase chain reaction(s) (PCRs)
in defining resistance to gram-negatives in clinical microbiology laboratory
single and multiplex endpoint, 325–326
single and multiplex real-time, 326–327
Polymerase chain reaction/electrospray ionization mass spectroscopy (PCR/ESI MS)
in defining resistance to gram-negatives in clinical microbiology laboratory, 332–333
Polymyxin(s), 391–414
as agents of last resort, 391–414
in ESBL–producing Enterobacteriaceae infections management
in hospital settings, 359
introduction, 391–393
mechanism of action of, 393
mechanisms of resistance of, 393–395
resistance to (See Polymyxin resistance)
Polymyxin B, 391–414
Polymyxin E, 391–414
Polymyxin resistance
prevention of, 404–405
antimicrobial stewardship in, 404–405
infection control in, 404
strategies to minimize, 398–404
combination therapy, 401–404
optimizing dosing regimens, 398–401
Polymyxin-resistant gram-negative bacilli
  clinical epidemiology of, 395–398
Postantibiotic era
  aversion of, 319
Pseudomonas aeruginosa
  MDR
    in the community, 382–383

R
Rapid antimicrobial susceptibility testing
  in defining resistance to gram-negatives in clinical microbiology laboratory, 330–331
Rapid biochemical tests
  in detection of ESBL and carbapenemase producers
    in defining resistance to gram-negatives in clinical microbiology laboratory, 325
Rapid whole-genome sequencing (WGS)
  in defining resistance to gram-negatives in clinical microbiology laboratory, 332
Relebactam
  on the horizon, 448
RG6080
  on the horizon, 448
RmtA, 529
RmtB-530, 529
RmtC, 530
RmtD, 530
RmtE, 530
RmtF, 530–531
RmtG, 531
RmtH, 531

S
S-649266
  in clinical development, 455–456
Semisynthetic lipoglycopeptides
  in bacteremia-related MRSA management, 493–496
SHVs
  historic evolution of, 349–350
Siderophore cephalosporin(s)
  in clinical development, 455–456
Single and multiplex endpoint polymerase chain reactions (PCRs)
  in defining resistance to gram-negatives in clinical microbiology laboratory, 325–326
Single and multiplex real-time polymerase chain reactions (PCRs)
  in defining resistance to gram-negatives in clinical microbiology laboratory, 326–327
Solid organ transplantation (SOT)
  antibiotic-resistant infections in
    inappropriate empiric antibiotics and, 471
    prevalence of, 467
    risk factors for, 467–471
    treatment challenges, 466–472
SOT. See Solid organ transplantation (SOT)
Standard antimicrobial susceptibility testing (AST) methods
  in defining resistance to gram-negatives in clinical microbiology laboratory, 324–325
Staphylococcus aureus
  methicillin-resistant (See Methicillin-resistant Staphylococcus aureus (MRSA))
Streptococcus pneumoniae
  antibiotic resistance in
    in HIV patients, 480
Streptogramins
  resistant to VRE infections
    mechanisms in mediation of, 424–425
Sulfone(s)
  novel
    in preclinical development, 452–453

T
Telavancin
  in bacteremia-related MRSA management, 496
TEM
  historic evolution of, 349–350
3’-Thiobenzoyl cephalosporins
  in preclinical development, 456
Tigecycline
  in bacteremia-related MRSA management, 499
  in ESBL–producing Enterobacteriaceae infections management
    in hospital settings, 359
Transplantation(s)
  solid organ
    antibiotic-resistant infections in (See also Solid organ transplantation (SOT))
      treatment challenges, 466–472
Trimethoprim-sulfamethoxazole resistance, 481
Tuberculosis (TB)
  drug-resistant, 509–522 (See also Drug-resistant tuberculosis (DR-TB))

V
Vancomycin
  in bacteremia-related MRSA management, 492–493
    combination therapy with, 499–500
Vancomycin-resistant enterococci (VRE), 415–439
  antibiotic resistance to, 421
    mechanisms in mediation of
      for daptomycin, 421–423
      for glycyclidones, 425
      for lipoglycopeptides, 424
      for oxazolidionones, 423–424
      for streptogramins, 424–425
    in the community, 380–381
    host colonization of, 418–419
    introduction, 415
profile of, 416–418

treatment of
  therapeutic strategies in, 425–430
  daptomycin combinations, 427–428
  dual β-lactam combinations, 427
  new strategies, 429–430

virulence factors, 419–421

VRE. See Vancomycin-resistance enterococci (VRE)

W

WGS. See Whole-genome sequencing (WGS)

Whole-genome sequencing (WGS)
  in defining resistance to gram-negatives in clinical microbiology laboratory, 328–329
  rapid WGS, 332